Episurf Medical (NASDAQ: EPIS B) is obtaining another new patent in China. The Chinese Patent Office SIPO has issued Notice of allowance for a patent related to Episurf Medical’s technology for visualisaton of joint damage. The patent, entitled “Method and node for manufacturing a surgical kit for cartilage repair”, covers the medical image segmentation process used for joint damage visualisation as well as for manufacturing of Episurf Medical’s patient-specific joint implants and surgical instruments.
“This is the first patent within this important patent family to be granted. Image segmentation is a very important field for us where we are working intensely to strengthen our intellectual property rights, as there is a global trend within medtech towards more and more patient-specific solutions. We are thus very happy for this patent progress” comments Pål Ryfors, CEO, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11.30 CEST on 25 October 2017.